Michael A. O’Donnell
University of Iowa · 387 works · 12,126 citations · h-index 60
Top works
- Extent of Pelvic Lymphadenectomy and Its Impact On Outcome in Patients Diagnosed With Bladder Cancer: Analysis of Data From the Surveillance, Epidemiology and End Results Program Data Base
- BCG immunotherapy of bladder cancer: 20 years on
- Nephropathy requiring dialysis after percutaneous coronary intervention and the critical role of an adjusted contrast dose
- Pathophysiological role of T lymphocytes in renal ischemia-reperfusion injury in mice
- Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial
- CLINICAL AND PATHOLOGICAL CHARACTERISTICS OF MICROPAPILLARY TRANSITIONAL CELL CARCINOMA: A HIGHLY AGGRESSIVE VARIANT
- Management of stage T1 tumors of the bladder: International Consensus Panel
- Final results from a national multicenter phase II trial of combination bacillus Calmette-Guérin plus interferon α-2B for reducing recurrence of superficial bladder cancer☆
- The Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2) Collaborative Quality Improvement Initiative in Percutaneous Coronary Interventions
- The Impact of Age on the Response of Patients With Superficial Bladder Cancer to Intravesical Immunotherapy
- SALVAGE INTRAVESICAL THERAPY WITH INTERFERON-α2B PLUS LOW DOSE BACILLUS CALMETTE-GUERIN IS EFFECTIVE IN PATIENTS WITH SUPERFICIAL BLADDER CANCER IN WHOM BACILLUS CALMETTE-GUERIN ALONE PREVIOUSLY FAILED
- Streptococcal preparation OK-432 is a potent inducer of IL-12 and a T helper cell 1 dominant state
- Multi-Institution Evaluation of Sequential Gemcitabine and Docetaxel as Rescue Therapy for Nonmuscle Invasive Bladder Cancer
- Consensus statement on best practice management regarding the use of intravesical immunotherapy with BCG for bladder cancer
- INTERIM RESULTS FROM A NATIONAL MULTICENTER PHASE II TRIAL OF COMBINATION BACILLUS CALMETTE-GUERIN PLUS INTERFERON ALFA-2B FOR SUPERFICIAL BLADDER CANCER
- IFN-alpha 2B enhances Th1 cytokine responses in bladder cancer patients receiving Mycobacterium bovis bacillus Calmette-Guérin immunotherapy.
- The Role of Bacillus Calmette-Guérin in the Treatment of Non–Muscle-Invasive Bladder Cancer
- Eradication of murine bladder carcinoma by intratumor injection of a bicistronic adenoviral vector carrying cDNAs for the IL-12 heterodimer and its inhibition by the IL-12 p40 subunit homodimer
- SUPERFICIAL BLADDER CANCER: THE ROLE OF INTERFERON-alpha
- Prognosis of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer by immunological urinary measurements: statistically weighted syndrome analysis.